Member Info for shan

further progress todays guys...looking good once revenues come in from these new offerings...ps hope ur both well!

will be interesting to see if any activity north pre-results mate. hope ur well too!

Mmmm unsure tbh....financials heavily skewed due to big cash pile (more than mcap!). Would want to see actual revenues too before seeing how efficient model is.....also in India so not sure best environment for stability/reliability etc.....all IMHO! Jolly what is basis for confidence considering this....

jolly,...hope ur well mate will have a look at this tonight

mmmmmm.....interesting!!

as expected, net profit at end of year too. first time in a while - recovery play potential!

Successful completion of Genedrive® Indian clinical trials and regulatory submission Epistem Holdings Plc (LSE: EHP), the personalised medicine and biotechnology company, announces today the successful completion of its Genedrive® Indian clinical evaluation study and the regulatory submission with the Drug Controller General of India (DCGI) of its first test for the diagnosis of Tuberculosis and Rifampicin antibiotic resistance (TB). Epistem is now awaiting approval from the Indian regulator for a license to import and sell its first major infectious disease assay for TB, which is anticipated early in 2015.

Incredible results!!! £8M + Free Cash Flow!!!

some highlights from interims: "Turnaround in operating performance" o Planning permission secured from the Isle of Man Government to build a 240 bedroom portable hotel for the period of the TT races on the island on a permanent basis o Five year agreement with Silverstone Circuits that will see the two companies working closely together to develop the offering at the racetrack · Next Generation Portable Hotel o The new Snoozebox event hotel room will be launched in November 2014 and ramp up of production of the new fleet will commence defo heading in right direction!

recd by midas share tips weekend " A 9.9p full-year dividend is expected for 2014, rising to 10.4p the year after. Midas verdict: Manx is a solid stock and the interims have shown it can deliver. Investors who bought in March should hold. Others in search of income should consider buying in."

recd in midas share tips today. "Midas verdict: Premier Farnell’s shares were 240p in March. Today they are 176p, reflecting concerns about growth in the electronics industry and the wider economy. The fall seems overdone and these shares should recover. The company is also hosting a special day for large investors this week, which should provide reassurance about the future. Buy the shares now."

ex-divi yesterday mate

ex-divi yesterday so out the way

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following trading update for the six months to 30 September 2014, in advance of releasing its interim results on Wednesday 26 November 2014. Financial update Turnover is expected to be £5.69m, slightly ahead of last year's first-half result (30 September 2013: £5.59m). Due to careful management of costs and an improved segmental mix of business, profit before tax (before acquisition costs, share based payments, IFRS-related discount unwinds and amortisation of intangible assets) is expected to be approximately £0.56m, some 30% ahead of the £0.43m earned in the previous half-year period to 30 September 2013.

It does if u invested for income and hold long term.

Hi mate just got an email about this so will do some more research later regards...mentioned recent director buy

Making the right noises it seems....definitely recovery play potential once dust settles.

Servoca, the specialist outsourcing and recruitment solutions provider, announces an update on trading following its year ended 30 September 2014. The Company is pleased to report that results for the year ended 30 September 2014 will be significantly ahead of market expectations and the Board is encouraged by the excellent performance of the Group. The September period, which is important for the Group's Education recruitment businesses, was very positive and showed another marked improvement on the prior year. Trading in the second half also saw a substantial improvement in the performance and profitability of the Company's Healthcare businesses. The performance for the year and the platform established give the Board confidence for continuing growth in 2015. Servoca expects to announce its preliminary results to 30 September 2014 on 4th December 2014.

Price to free cash flow of just 6.5 ish....looking good imho.

used to be SSP - just out of interest!!!